-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Global Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREIQVIA Careers
Featured Careers
Stay Connected
WE'RE HIRING
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBlog
Psoriasis drives autoimmune sales growth
Mar 11, 2019
Patient volume unchanged
The size of the patient population for this disease has been a driving factor for investment, with an estimated prevalence range of 0.5% up to 11% in some populations (Michalek et al., 2017), compared to rheumatoid arthritis prevalence of just 0.5-1% (Gabriel, 2001). However, as shown by the below graphic, the volume of the market is expected to show modest growth, which is in line with the rest of the prescription market over the next 10 years. It is the large forecast growth in sales, driven by expensive biologic therapies that sets this disease apart.
Confidence in biologic therapy for psoriasis recovered
The uptake of biologic therapy was comparatively slow in Dermatology initially, likely influenced by the issues seen with the first biologic for psoriasis, a CD11a inhibitor. This injectable treatment was launch in 2003 but subsequently removed from the market in 2008 due to serious side-effects, leaving Dermatologists sceptical of novel target biologics. The TNF inhibitor biologics have since proven the safety and efficacy of biologic treatment in psoriasis, despite the need for higher dosing than other autoimmune diseases at times, and uptake has been steady for this disease.
Biologic use in a small proportion of patients
Many of the large psoriasis patient pool goes untreated. Within the treated population IQVIA volume data suggests that 80% of the comparative prescription drug volume (patient days) is for topical therapies, leaving 20% of the patient days for a form of systemic treatment in 2017. Patients often use treatments in combination, so it is important to note that the patient days metric does not translate directly to patient numbers.
The use of systemic treatments does vary by region, driven by both prescribing habit and patient access to the more expensive treatments. Europe, the Americas and MENA show higher proportional use of topical therapies.
IQVIA data suggests that an even smaller proportion of patient days, just under 8%, were for a biologic therapy in 2017, as shown in the graphics below.
The below forecast models switching of patient volume to new launches from existing biologics, but if just a small proportion of currently topically treated patients, also receive a new biologic, the size of this market could grow considerably more. The below graphic also shows how the proportion of sales for biologic therapies is eroded over the forecast period by biosimilar launches, and novel oral kinase and PDE4 inhibitors.
* 2018 contains Q3 2018 historical data.
Now a new generation of Dermatologists and a new generation of biologics combine to show the events of a decade ago no longer shape prescribing. The market looks set to show significant sales growth as patients gain access to more of these highly effective treatments, and the effect is expected to spread to other dermatologic disorders as biologic treatments launch in areas such as atopic dermatitis.
For more information on brand and country specific forecasts in any disease, please contact IQVIA and request a demonstration of Forecast Link, an online tool containing 5 years historical and 10 years of forecast data in 73 countries, for 10,000 drugs and over 600 diseases.
References:
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212.
Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269–281.